Verily, company under the umbrella of Alphabet, presents a new smart watch

Adjust Comment Print

Verily, the health technology subsidiary of Google's parent company Alphabet today talked about its latest project: a smartwatch packed with sensors, an always-on display, a big battery, and a long-lasting battery that's meant for longitudinal studies. And the fact that it looks and acts like a standard wristwatch goes a ways toward making the data collection process less obtrusive than more traditional vital-gathering devices. The team at Verily designed this smartwatch keeping in mind the requirements of high-quality signals and seamless usage.

The Verily smartwatch will not be for sale. The device comes with multiple environmental and psychological sensors.

All data are encrypted on the device for security purposes, as the watch is able to store up to a week's worth of health data - removing the need to sync the device. While the longer battery is created to ensure that these physiological and environmental signs can be monitored continuously and over much lengthier periods of time - with a view to providing greater longitudinal data.

Читайте также: Minecraft coming to Nintendo Switch

Paired with a "powerful processor", real-time algorithms can run on the device, with OTA software updates adding new algorithms and improved user interfaces. The blog post says the device can track "relevant signals for studies spanning cardiovascular, movement disorders, and other areas". The display is low power and high resolution for an appealing look and a robust user interface.

Currently, only time and certain instructions are displayed. Rather than focus on displaying info and providing functionality, the Study Watch collects and stores important health data for health studies. On-device data is encrypted, with that information uploaded and processed using Verily backend algorithms and machine learning tools. The unit's previous projects include the smart contact lens, but many of its initiatives involve partners like the GlaxoSmithKline, Sanofi, and the U.S. National Institutes of Health (NIH). "This infrastructure is highly scalable and can serve population studies consisting of large volumes of data", the company said.

При любом использовании материалов сайта и дочерних проектов, гиперссылка на обязательна.
«» 2007 - 2017 Copyright.
Автоматизированное извлечение информации сайта запрещено.

Код для вставки в блог